What is Eroxon ® Intense and when will it be available?
Eroxon® Intense is an additional treatment option for erectile dysfunction that is aimed at helping the cohort of men that may prefer a stronger sensation from Eroxon®.
We are expecting regulatory approval in the EU and USA by the end of 2025.
What is WSD4000 and when will it be available?
WSD4000 is a topical gel that is being specifically designed to treat symptoms of sexual dysfunction in women, providing improvements in sexual desire, arousal, lubrication, pain during intercourse, orgasm and overall sexual satisfaction. Currently, no regulatory approved topical treatment for sexual dysfunction in women is available over the counter.
We are unable to provide a firm date for when WSD4000 will become available. A further pre-submission meeting with the FDA has taken place, where good progress was made to clearly define the product’s indication for use, the potential claims, and how these should be proven during the clinical phase of development. Following the FDA meeting and the success of the study we are proceeding with an Early Feasibility Study to be completed in the first half of 2026. This will enable the Group to consider refinements to the methodology in a population more representative of the target user and therefore hope to increase efficacy still further, as well as further inform on perceptions of the product. WSD4000 has the potential to be an effective breakthrough treatment for the common symptoms of sexual dysfunction in women and is a large and significant commercial opportunity in a market where there are very few treatments available to women .